fda glp-1 enforcement news october 2025 is moving to restrict mass-marketed compounded products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger to protect patients from unverified The FDA has approved certain
Description
Coverage of the drugs for weight loss would end on Oct
Kidney data continue to mature

Important changes include: (1) the decision to treat high-risk individuals with a glucagon-like-peptide 1 (GLP-1) receptor agonist or sodiumglucose cotransporter 2 (SGLT2) inhibitor to reduce major adverse cardiovascular events (MACE), hospitalisation for heart failure (hHF), cardiovascular death or chronic kidney disease (CKD) progression should be considered independently of baseline HbA1c or individualised HbA1c target
These ingredients have been studied for their ability to help support glucose metabolism, support digestion, and maintain a healthy inflammatory response

Online weight loss programs provide medical support with prescription GLP-1 medications and clinician oversight through convenient telehealth visits.
